期刊文献+

益气化痰方联合化疗治疗晚期非小细胞肺癌的临床价值

Clinical value of Yiqi Huatan recipe combined with chemotherapy in the treatment of advanced non-small cell lung cancer
在线阅读 下载PDF
导出
摘要 目的探讨益气化痰方联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床价值。方法选取2020年3月至2021年6月于本院治疗的88例NSCLC患者作为研究对象,按照随机数字表法分为联合组与单一组,每组44例。单一组实施单一化疗(多西他赛+顺铂),联合组在单一组基础上给予益气化痰方治疗。比较两组临床疗效、生命质量及不良反应发生情况。结果联合组治疗总有效率为63.64%,高于单一组34.09%,差异有统计学意义(P<0.05)。治疗后,两组身体功能、情感功能、社会功能、角色功能、认知功能及总评分均高于治疗前,且联合组高于单一组,差异有统计学意义(P<0.05)。联合组白细胞减少、恶心呕吐、贫血、周围神经中毒发生率明显低于单一组,差异有统计学意义(P<0.05)。结论益气化痰汤联合化疗治疗NSCLC疗效确切,可显著改善患者的临床症状和生命质量,且安全性较高,值得临床推广应用。 Objective To explore the clinical value of Yiqi Huatan recipe combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 88 NSCLC patients who were treated in our hospital from March 2020 to June 2021 were selected as the research subjects,and they were randomly divided into the combined group and the single group according to the random number table method,with 44 cases in each group.The single group received single chemotherapy(docetaxel+cisplatin),while the combined group received Yiqi Huatan recipe treatment on the basis of the single group,the clinical efficacy,quality of life,and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the combined group was 63.64%,which was higher than 34.09%in the single group,and the difference was statistically significant(P<0.05).After treatment,the physical function,emotional function,social function,role function,cognitive function,and total score of the two groups were higher than before treatment,and the combined group was higher than the single group,and the differences were statistically significant(P<0.05).The incidence of leukopenia,nausea and vomiting,anemia,and peripheral neuropathy in the combined group were significantly lower than those in the single group,and the differences were statistically significant(P<0.05).Conclusion The combination of Yiqi Huatan recipe and chemotherapy has a significant therapeutic effect on NSCLC,which can significantly improve the clinical symptoms and quality of life of patients,it has high safety and is worthy of clinical promotion and application.
作者 刘理 袁芳彬 刘毛毛 LIU Li;YUAN Fangbin;LIU Maomao(Department of Traditional Chinese Medicine,the Third People's Hospital of Jiujiang,Jiujiang,Jiangxi,332000,China)
出处 《当代医学》 2023年第24期118-120,共3页 Contemporary Medicine
关键词 益气化痰方 化疗 非小细胞肺癌 生命质量 不良反应 Yiqi Huatan recipe Chemotherapy Non-small cell lung cancer Quality of life Adverse reaction
  • 相关文献

参考文献15

二级参考文献152

  • 1谭梅傲,曹敏,佘世锋,兰绍阳,欧海亚.基于网络药理学探讨“紫菀-款冬”药理作用机制[J].中药材,2019,42(7):1646-1651. 被引量:24
  • 2周晴晴,李慧杰,李秀荣.中医药逆转EGFR-TKIs治疗非小细胞肺癌获得性耐药研究进展[J].亚太传统医药,2020(9):206-210. 被引量:4
  • 3杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1630
  • 4周岱翰,林丽珠,周宜强,罗荣城,刘魁凤,贾英杰,陈继跃,牛喜伟,苏碧茹,鲁江,王树堂.益气除痰法延长非小细胞肺癌中位生存期的作用[J].中医杂志,2005,46(8):600-602. 被引量:81
  • 5孙燕.内科肿瘤学[M].北京:人民卫生出版社,2006:102.
  • 6Quoix E, Westeel V, Zalcman G, et al. Chemotherapy in elderly patients with advanced non -small cell lung cancer[ J ]. Lung Cancer,2011,74: 364 - 368.
  • 7Gajra A, Lichtman SM. Treatment of advanced lung cancer in the elderly [ J]. Hosp Pratt (Minneap) ,2011,39 : 107 - 115.
  • 8Non - Small Cell Lung Cancer Collaborative Group. Chemotherapy in non - small cell lung cancer: a meta - analysis using updated individual pa- tients data from 52 randomised clinical trials[J]. BMJ, 1995,311:899 -909.
  • 9Gridelli C. The ELVIS trial:a phase Ⅲ study of single- agent vinorelbine as first - line treatment in elderly patients with advanced non - small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study [ J ]. Oncolo- gist,2001,6:4 -7.
  • 10Kudoh S, Takeda K, Nakagawa K, et al. Phase Ⅲ study of docetaxel com- pared with vinorelbine in elderly patients with advanced non - small - cell lung cancer:results of the West Japan Thoracic Oncology Group Trial( WI- TOG 9904) [ J]. J Clin Oneol,2006,24:3657 -3663.

共引文献228

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部